NewsBenzingaLUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24 LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24 Benzinga 2026.09.24 11:38 (GMT+0) Open on Benzinga Other news Ross Gerber Tells Investors to 'Be Patient' on Anthropic Stock After Post-IPO Slide: ‘That Would Be a Gift’ Pentagon Memo Restricts Casual US-Canada Military Contact, Sen. Mike Rounds Says Scaramucci Takes Aim at Sean Hannity Over Pope’s Iran War Criticism, Says ‘Trump Is His New Jesus’ Van Hollen Calls Senate Democratic Leader Race 'Wide Open' as Prediction Markets Favor Schumer Trump Says He'll Work With Democrats to Cap Credit Card Rates at 10%: 'I Would Do It' JB Pritzker Says Americans are ‘Tired of the Corruption in Washington’ as He Urges Leaders to ‘Repair the Damage’ Left by the Trump Administration
Ross Gerber Tells Investors to 'Be Patient' on Anthropic Stock After Post-IPO Slide: ‘That Would Be a Gift’
JB Pritzker Says Americans are ‘Tired of the Corruption in Washington’ as He Urges Leaders to ‘Repair the Damage’ Left by the Trump Administration